Should you buy Immix Biopharma (IMMX)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Single Asset Pipeline Concentration↑Improving
- Cash Burning No Revenue→Stable
- Analyst Target Upside↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Concentration
Trip ifA clinical hold or supply disruption delays NXC-201 by more than 2 quarters.
- P2Cash Burning No Revenue
Trip ifQuarterly loss per share widens to more than $0.28 for 2 consecutive quarters.
- P3Analyst Target Upside
Trip ifAverage analyst target falls below $12.00 from the current $21.25.
- P4Weak Momentum Capitulation Risk
Trip ifMomentum score stays below 2.0 for 2 consecutive months.
- P5Inconsistent Earnings Execution
Trip ifEPS surprise stays below -25% for 2 consecutive quarters.
How the engine reached this verdict
TrendMatrix's engine output for Immix Biopharma, Inc. (IMMX) is SELL_IF_HOLDING with medium conviction, score 4.9/10 at $8.13. The momentum gate failed (3.2 vs threshold 4.5), producing a SELL engine output.
The dominant failed gate is momentum at 3.2 vs threshold 4.5. SELL flips back toward HOLD if momentum recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is INSIDER:OK.
On the bear side: Concentration risk — Pipeline: NXC-201; Concentration risk — Supplier: third-party CMOs; DATA_ISSUE: analyst_target_implausible (raw $24.43 vs price $8.12 — ratio 3.0×). Rejected, falling back to technical TP.. Active engine warnings: DATA_ISSUE: analyst_target_implausible (raw $24.43 vs price $8.12 — ratio 3.0×). Rejected, falling back to technical TP., Quality below floor (1.6 < 4.0), V9 Gate Failed: MOMENTUM:3.2<4.5.
The engine's exit framework anchors to a tactical sell band near $8.13, with structural invalidation at $7.61. The asymmetric R:R against a reversal hypothesis is 0.00 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates IMMX — 10-dimension breakdown →
Bear case
- ▸Concentration risk — Pipeline: NXC-201
- ▸Concentration risk — Supplier: third-party CMOs
- ▸DATA_ISSUE: analyst_target_implausible (raw $24.43 vs price $8.12 — ratio 3.0×). Rejected, falling back to technical TP.